保妇康栓治疗CINⅠ伴高危HPV感染的疗效观察  

Clinical efficacy of Baofukang suppository in treatment of CIN Ⅰ with high-risk human papillomaviras infection in patients

作　　者：郭大庆[1] 廖庆梅[2] 王祥珍[2] 

机构地区：[1]深圳市南山区妇幼保健院药剂科,深圳518052 [2]深圳市南山区妇幼保健院妇科,深圳518052

出　　处：《北方药学》2015年第8期27-28,共2页Journal of North Pharmacy

摘　　要：目的：探讨保妇康栓治疗CIN1伴人乳头瘤病毒（HPV）感染的临床疗效及安全性。方法：选取2012年6月~2014年6月确诊CIN1伴人乳头瘤病毒（HPV）感染的患者90例,随机分为A组、B组及C组,各30例,A组使用保妇康栓治疗、B组使用重组人干扰素α-2b阴道泡腾胶囊治疗、C组未用药物治疗,对比3组患者治疗高危HPV感染转阴情况以及不良反应,所得数据采用SPSS 16.0进行分析。结果：治疗6个月HPV转阴率A组86.7%、B组70.0%,A组明显好于B组,B组HPV转阴率优于C组的46.7%,差异有统计学意义（P〈0.05）,3组患者均无严重不良反应。结论：保妇康栓治疗CIN1伴HPV感染疗效确切、不良反应小,值得临床推广。Objective：To investigate clinical efficacy and safety of Baofukang suppository in treatment of high- risk human papillomaviras infection in patients with cervical intraepithelial neoplasia Ⅰ（CIN Ⅰ）.Methods：A total of 90 patients diagnosed with CIN Ⅰ and cervical HPV infection during Jun.2012 to Jun.2014 were randomly divided into group A,group B and group C with 30 cases in each group.Women of group A received treatment with Baofukang suppository,group B with recombinant human interferon a-2b vaginal effervescent capsules,group C did not received any medication.The therapeutic results for high-risk HPV infection change to negative patients and adverse reactions were compared between the three groups.Data obtained were analyzed using the software SPSS16.0.Results：The high-risk HPV infection change to negative rate was 86.7% in group A,70.00 % in group B,46.7% in group C,indicating that the treatment efficacy was better in group A than in group B,the treatment efficacy was better in group B than in group C,the difference was significant（P 0.05）.There were no seriousadverse reactions in the three groups. Conclusion：Treatment of Baofukang suppository for CIN Ⅰ with high-risk human papillomaviras infection in patients resulted in significant efficacy and few adverse reactions,which was worthy ofclinical application.

关 键 词：保妇康栓 人乳头瘤病毒 宫颈上皮内瘤变 临床疗效 

分 类 号：R737.33[医药卫生—肿瘤]